If you have been reading about bremelanotide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-04-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
| Property | Value | Notes |
|---|---|---|
| Primary target | Melanocortin receptors | Mainly the MC4R subtype |
| Route of administration | Injection | Typically subcutaneous |
| Time to peak | About 60 minutes | After subcutaneous dosing |
| Elimination half-life | Roughly 2 to 3 hours | Values vary across reports |
| Metabolic pathway | Peptidase hydrolysis | Cleared by the kidneys |
Routine characterisation of bremelanotide relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nm, where the peptide backbone absorbs. Mass spectrometry, typically in tandem mode with electrospray ionisation, confirms identity and supports quantification in biological matrices. Additional checks include amino acid analysis, peptide mapping after enzymatic digestion, and confirmation of the lactam bridge, since incomplete cyclisation produces a mass-shifted by-product. Purity values above 95 percent are common in reference-grade material, though reports vary in how strictly related substances are resolved from the parent peak.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
Lyophilised peptide is generally held below minus twenty degrees Celsius, protected from light and moisture, because hydrolysis and oxidation accumulate faster at ambient temperature. Once reconstituted, solutions are typically kept between two and eight degrees Celsius and used within a short window defined by the supplier. Repeated freeze-thaw cycles are avoided since they promote aggregation and loss of soluble material. Container material matters as well, because peptides adsorb to certain plastics and glass surfaces at low concentration. Stability figures supplied by a vendor apply only to the specific lot and buffer that were tested.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography combined with mass spectrometry. A gradient of water and acetonitrile containing trifluoroacetic acid is a common mobile phase, and ultraviolet detection near 214 nanometres responds to the peptide backbone. Mass spectrometry confirms the expected molecular mass and helps reveal truncation or oxidation products. Purity is reported as a peak-area percentage, a figure that depends on the wavelength and gradient used, so values from different laboratories are not always directly comparable. Peptide mapping and amino acid analysis provide additional confirmation when required.
== History == Sigma Chemical Company of St. Louis and Aldrich Chemical Company of Milwaukee were both American specialty chemical companies when they merged in August 1975. The company grew throughout the 1980s and 1990s, with significant expansion in facilities, acquisitions and diversification into new market sectors.
The improved safety and tolerability profile of the SSRIs in patients with MDD, compared with TCAs and MAOIs, represented yet another important advance in the treatment of depression. Since the late 1980s, SSRIs have dominated the antidepressant drug market. Today, there is increased interest in antidepressant drugs with broader mechanisms of action that may offer improvements in efficacy and tolerability. In 1993, a new drug was introduced to the US market called venlafaxine, a serotonin–norepinephrine reuptake inhibitor. Venlafaxine was the first compound described in a new class of antidepressant substances called phenylethylamines. These substances are unrelated to TCA and other SSRIs. Venlafaxine blocks the neuronal reuptake of serotonin, norepinephrine, and, to a lesser extent, dopamine in the central nervous system. In contrast with several other antidepressant drugs, venlafaxine can induce a rapid onset of action mainly due to a subsequent norepinephrine reuptake inhibition. See timeline in figure 1.
Trabectedin, sold under the brand name Yondelis, is an antitumor chemotherapy medication for the treatment of advanced soft-tissue sarcoma and ovarian cancer. The most common adverse reactions include nausea, fatigue, vomiting, constipation, decreased appetite, diarrhea, peripheral edema, dyspnea, and headache. It is sold by Pharma Mar S.A. and Johnson and Johnson. It is approved for use in the European Union, Russia, South Korea and the United States. The European Commission and the U.S. Food and Drug Administration (FDA) granted orphan drug status to trabectedin for soft-tissue sarcomas and ovarian cancer. It was originally discovered in the sea squirt Ecteinascidia turbinata. Because natural yields are extremely low, its supply is based on a semisynthetic process starting from a chemical obtained from the bacterium Pseudomonas fluorescens.
Sources: en.wikipedia.org
semiconservative replication The standard mode of DNA replication that occurs in all living cells, in which each of the two parental strands of the original double-stranded DNA molecule are used as template strands, with DNA polymerases replicating each strand separately and simultaneously in antiparallel directions. The result is that each of the two double-stranded daughter molecules is composed of one of the original parental strands and one newly synthesized complementary strand, such that each daughter molecule conserves the precise sequence of information (indeed the very same atoms) from one-half of the original molecule. Contrast conservative replication and dispersive replication.
=== Aliases === Hodgkin published as "Dorothy Crowfoot" until 1949, when she was persuaded by Hans Clarke's secretary to use her married name on a chapter she contributed to The Chemistry of Penicillin. By then she had been married for 12 years, given birth to three children and been elected a Fellow of the Royal Society (FRS). Thereafter she would publish as "Dorothy Crowfoot Hodgkin", and this was the name used by the Nobel Foundation in its award to her and the biography it included among other Nobel Prize recipients; it is also what the Science History Institute calls her. For simplicity's sake, Hodgkin is referred to as "Dorothy Hodgkin" by the Royal Society, when referring to its sponsorship of the Dorothy Hodgkin fellowship, and by Somerville College, after it inaugurated the annual lectures in her honour. The National Archives of the United Kingdom refer to her as "Dorothy Mary Crowfoot Hodgkin"; on a variety of plaques commemorating places where she worked or lived, e.g. 94 Woodstock Road, Oxford, she is "Dorothy Crowfoot Hodgkin". In 2022, the Department of Biochemistry in Oxford renamed its much expanded building after Hodgkin, calling it the "Dorothy Crowfoot Hodgkin Building".
Brigade Infantry: 1st Battalion (Airborne), 505th Infantry 2nd Battalion (Airborne), 505th Infantry 1st Battalion (Airborne), 508th Infantry Brigade Artillery: 2nd Battalion (Airborne), 321st Artillery (105mm) Brigade Aviation: Company A, 82nd Aviation Battalion Brigade Reconnaissance: Troop B, 1st Squadron (Armored), 17th Cavalry Company O (Ranger), 75th Infantry Brigade Support: 82nd Support Battalion 58th Signal Company Company C, 307th Engineer Battalion (Airborne) 408th Army Security Agency Detachment 52nd Chemical Detachment 518th Military Intelligence Detachment 307th Medical (Airborne) Headquarters and Alpha Company The deployment of the 3rd Brigade took place with significant problems and controversy. In The Rise and Fall of an American Army: US Ground Forces in Vietnam, 1965–1973, author Shelby L. Stanton describes how, other than the 82nd, only two under-strength Marine and four skeletonized Army divisions were left stateside by the beginning of 1968. The U.S. Military Assistance Command, Vietnam (MACV), desperate for additional manpower, wanted the division to deploy to Vietnam, and the Department of the Army, wishing to retain its "sole readily deployable strategic reserve, the last real vestige of actual Army divisional combat potency in the United States left to the Pentagon," compromised by sending the 3d Brigade. As Stanton wrote:
Sources: en.wikipedia.org
It primarily activates specific subtypes in the melanocortin receptor family. These receptors are G protein-coupled and mediate signaling mainly within the central nervous system.
It activates pigmentation-related receptors more weakly. This selectivity is thought to alter its side effect profile.
Injection is the most common route. Nasal administration has been studied as well, though absorption varies considerably.
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.